Is Codexis profitable in 2026?

Codexis posted a Q4 2025 net income of $9.6 million on $38.9 million revenue, but FY2025 still showed a $44.0 million net loss, and Q1 2026 posted an $8.7 million net loss despite revenue nearly doubling to $15.2 million, as of May 7, 2026.

Did Codexis have layoffs?

Yes. Codexis cut 24% of its workforce in November 2025 alongside a CEO transition to Alison Moore, following an earlier 18% layoff in November 2022; headcount fell to 146 employees by December 31, 2025, down 22.34% year over year.

Could AI replace Codexis's enzyme engineering work?

AI protein-design tools are commoditizing enzyme-variant design, and rival Ginkgo Bioworks launched an AI foundation-model partnership with Google Cloud in 2025, but Codexis's 250+ patents, 20 years of screening data, and FDA regulatory engagement for GMP biomanufacturing are harder for pure AI competitors to replicate as of May 2026.

Who is Codexis's biggest competitor?

Ginkgo Bioworks and Novonesis (the merged Novozymes/Chr. Hansen enzyme giant) are Codexis's main threats; Ginkgo is better capitalized and unblocked from entering enzymatic siRNA manufacturing, the exact market Codexis's ECO Synthesis platform is targeting as of March 2026.

What is Codexis's ECO Synthesis platform and is it commercial yet?

ECO Synthesis is Codexis's enzymatic siRNA manufacturing platform, not yet at commercial scale as of May 2026; it has a 55-opportunity pipeline across 40 companies, a signed 50g siRNA batch agreement (March 2026), and plans to scale to 0.5kg by end of 2026 with GMP production targeted for end of 2027.

Codexis is a standalone, publicly traded company on NASDAQ under ticker CDXS, with no parent company; its market capitalization was approximately $180 million as of July 24, 2026, trading around $1.48 per share.

Biotech tools companies · United States

Codexis

codexis.com ↗

Codexis engineers enzymes for drug manufacturing, now betting on enzymatic siRNA production.

Losing its protection

Assessed 24 July 2026 · Evidence as of 24 July 2026

The structural protection is eroding.

On the recordSince 24 July 2026 · Checkable from August 12, 2026 · Every call on the record Checkpoint: Q2 2026 earnings, watch for signed CDMO contracts from the 55-opportunity pipeline

The call

Codexis is shrinking a business it knows how to run to chase one it hasn't proven yet, with cash and rivals both closing in before 2027.

Codexis designs enzymes, special proteins that speed up chemical reactions used to make medicines. The company built a real advantage over 20 years by getting very good at this work and filing hundreds of patents. Right now it is shrinking that proven business to bet everything on a new platform for making a specific type of medicine called siRNA, which it has not yet shipped or sold commercially. The risk is huge: Novonesis (the biggest traditional enzyme company) and Ginkgo Bioworks (better funded and partnered with Google) are also racing into siRNA manufacturing, while computer programs like AlphaFold are making enzyme design faster and cheaper for anyone to do, which erodes Codexis's old advantage. The company will run out of cash right around the time its new manufacturing facility is supposed to start working in late 2027, so it needs actual paying customers to sign up in the next year or two, not just promises of future interest.

Why

AI pressure: Ginkgo Bioworks (Google Cloud foundation-model partnership, 2025). Protein language models like AlphaFold and ESM are making enzyme design easier to copy, weakening Codexis's old directed-evolution edge. Could AI do the core job? Only partly.

Bigger players: Novonesis and Ginkgo Bioworks. Both are bigger, better funded, and free to enter enzymatic siRNA manufacturing just as Codexis tries to build that business from scratch. Could a giant copy it? Probably.

What protects it. 20+ years of directed-evolution patents, regulatory ties, and signed CDMO deals with Bachem, Nitto Denko Avecia, and Axolabs.

What would change this call

Codexis converts 55-opportunity pipeline into signed, scaled CDMO supply contracts by Q3 2026. Would show commercial demand is real, not just roadmap interest.
GMP siRNA facility construction start confirmed in H2 2026. Would show the 2027 commercialization timeline is on track.
Novonesis or Ginkgo Bioworks announces entry into enzymatic-siRNA manufacturing. Would show a better-capitalized rival is closing Codexis's window before it scales.

Key numbers

FY2025 revenue $70.4M, up ~19% YoY (2026-03-11)
Cash $65.1M as of Mar 2026, down from $78.2M (2026-05-07)
FY2025 net loss $44.0M (2026-03-11)

Named risks

Cash runway (through end of 2027) expires around the same time GMP facility is meant to reach full production. Severity: high
ECO Synthesis pipeline of 55 opportunities remains unconverted into signed scaled contracts. Severity: high
Stock trading near 52-week low ($1.48 vs $3.87 high) increases dilution or delisting risk. Severity: medium
Governance instability from CEO transition (Nov 2025) and director resignation (April 2026). Severity: medium
AI-native rivals commoditizing enzyme-variant design layer of core R&D. Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
Ginkgo Bioworks	losing to	Ginkgo launched AI foundation-model partnership with Google Cloud in 2025, unblocked from entering enzymatic siRNA manufacturing
Novonesis	losing to	Merged Novozymes/Chr. Hansen has deeper enzyme-manufacturing scale and no structural block from entering siRNA manufacturing
Solid Phase Organic Synthesis incumbents	contesting	Codexis benchmarks ECO Synthesis against conventional chemical oligo synthesis providers as of May 2026

Questions people ask

Is Codexis profitable in 2026?: Codexis posted a Q4 2025 net income of $9.6 million on $38.9 million revenue, but FY2025 still showed a $44.0 million net loss, and Q1 2026 posted an $8.7 million net loss despite revenue nearly doubling to $15.2 million, as of May 7, 2026.
Did Codexis have layoffs?: Yes. Codexis cut 24% of its workforce in November 2025 alongside a CEO transition to Alison Moore, following an earlier 18% layoff in November 2022; headcount fell to 146 employees by December 31, 2025, down 22.34% year over year.
Could AI replace Codexis's enzyme engineering work?: AI protein-design tools are commoditizing enzyme-variant design, and rival Ginkgo Bioworks launched an AI foundation-model partnership with Google Cloud in 2025, but Codexis's 250+ patents, 20 years of screening data, and FDA regulatory engagement for GMP biomanufacturing are harder for pure AI competitors to replicate as of May 2026.
Who is Codexis's biggest competitor?: Ginkgo Bioworks and Novonesis (the merged Novozymes/Chr. Hansen enzyme giant) are Codexis's main threats; Ginkgo is better capitalized and unblocked from entering enzymatic siRNA manufacturing, the exact market Codexis's ECO Synthesis platform is targeting as of March 2026.
What is Codexis's ECO Synthesis platform and is it commercial yet?: ECO Synthesis is Codexis's enzymatic siRNA manufacturing platform, not yet at commercial scale as of May 2026; it has a 55-opportunity pipeline across 40 companies, a signed 50g siRNA batch agreement (March 2026), and plans to scale to 0.5kg by end of 2026 with GMP production targeted for end of 2027.
Who owns Codexis?: Codexis is a standalone, publicly traded company on NASDAQ under ticker CDXS, with no parent company; its market capitalization was approximately $180 million as of July 24, 2026, trading around $1.48 per share.

Timeline

2026-05-08Q1 2026 earnings call: FY2026 guidance $72M-$76M reiterated, weighted to H2 2026
2026-05-07Q1 2026 results: revenue $15.2M, net loss $8.7M, cash $65.1M
2026-04-14Director Dennis Wolf resigns, board reclassification follows
2026-03-11FY2025 results announced: $70.4M revenue, $44.0M net loss
2026-03-10Codexis signs agreement to manufacture 50g siRNA batch via ECO Synthesis
2025-11-0624% workforce reduction and CEO transition to Alison Moore announced; $37.8M Merck deal executed
2022-11-30Codexis lays off 18% of staff amid program cuts and cash pressure
2016Codexis completes CodeEvolver technology transfer to GSK
2010-04Codexis goes public on NASDAQ
2002Codexis incorporated

Revision history

24 July 2026

First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.

In the same band

Element Biosciences Charles River Laboratories Bio-Techne Corporation